Molecular Biomarkers in Multiple Sclerosis

Overview

Journal J Neuroinflammation

Publisher Biomed Central

Date 2019 Dec 25

PMID 31870389

Citations 89

Authors

Tjalf Ziemssen

Katja Akgun

Wolfgang Bruck

Affiliations

Soon will be listed here.

Abstract

Multiple sclerosis (MS) is an inflammatory-neurodegenerative disease of the central nervous system presenting with significant inter- and intraindividual heterogeneity. However, the application of clinical and imaging biomarkers is currently not able to allow individual characterization and prediction. Complementary, molecular biomarkers which are easily quantifiable come from the areas of immunology and neurobiology due to the causal pathomechanisms and can excellently complement other disease characteristics. Only a few molecular biomarkers have so far been routinely used in clinical practice as their validation and transfer take a long time. This review describes the characteristics that an ideal MS biomarker should have and the challenges of establishing new biomarkers. In addition, clinically relevant and promising biomarkers from the blood and cerebrospinal fluid are presented which are useful for MS diagnosis and prognosis as well as for the assessment of therapy response and side effects.

Citing Articles

Circadian rhythmicity of symptomatic phenotypes in multiple sclerosis: the CircaMS study protocol and feasibility of biomarker collection.

Taccardi D, Gowdy H, Li V, Wing A, Baharnoori M, Finlayson M BMJ Open. 2025; 15(3):e095357.

PMID: 40044201 PMC: 11883553. DOI: 10.1136/bmjopen-2024-095357.

The role of Neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) in MS and AQP4-NMOSD: Advancing clinical applications.

Samadzadeh S, Sleator R eNeurologicalSci. 2025; 38:100550.

PMID: 39866832 PMC: 11762903. DOI: 10.1016/j.ensci.2025.100550.

Medical Digital Twin: A Review on Technical Principles and Clinical Applications.

Tortora M, Pacchiano F, Ferraciolli S, Criscuolo S, Gagliardo C, Jaber K J Clin Med. 2025; 14(2).

PMID: 39860329 PMC: 11765765. DOI: 10.3390/jcm14020324.

Investigating T-cell-derived extracellular vesicles as biomarkers of disease activity, axonal injury, and disability in multiple sclerosis.

Zagrodnik J, Blandford S, Fudge N, Arsenault S, Anthony S, McGrath L Clin Exp Immunol. 2025; 219(1).

PMID: 39798086 PMC: 11791523. DOI: 10.1093/cei/uxaf003.

Impact of serum neurofilament light on clinical decisions in a tertiary multiple sclerosis clinic.

van Lierop Z, Wessels M, Lekranty W, Moraal B, Hof S, Hogenboom L Mult Scler. 2024; 30(13):1620-1629.

PMID: 39420574 PMC: 11568682. DOI: 10.1177/13524585241277044.

References

Jones J, Phuah C, Cox A, Thompson S, Ban M, Shawcross J . IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest. 2009; 119(7):2052-61. PMC: 2701868. DOI: 10.1172/JCI37878. View

Novakova L, Axelsson M, Khademi M, Zetterberg H, Blennow K, Malmestrom C . Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis. J Neurochem. 2016; 141(2):296-304. DOI: 10.1111/jnc.13881. View

Coghe G, Fenu G, Lorefice L, Zucca E, Porta M, Pilloni G . Association between brain atrophy and cognitive motor interference in multiple sclerosis. Mult Scler Relat Disord. 2018; 25:208-211. DOI: 10.1016/j.msard.2018.07.045. View

McCreary M, Mealy M, Wingerchuk D, Levy M, DeSena A, Greenberg B . Updated diagnostic criteria for neuromyelitis optica spectrum disorder: Similar outcomes of previously separate cohorts. Mult Scler J Exp Transl Clin. 2018; 4(4):2055217318815925. PMC: 6293372. DOI: 10.1177/2055217318815925. View

Schwab N, Schneider-Hohendorf T, Pignolet B, Spadaro M, Gorlich D, Meinl I . PML risk stratification using anti-JCV antibody index and L-selectin. Mult Scler. 2015; 22(8):1048-60. DOI: 10.1177/1352458515607651. View

Calabresi P, Giovannoni G, Confavreux C, Galetta S, Havrdova E, Hutchinson M . The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007; 69(14):1391-403. DOI: 10.1212/01.wnl.0000277457.17420.b5. View

Ziemssen T, Kern R, Thomas K . Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach. BMC Neurol. 2016; 16:124. PMC: 4971685. DOI: 10.1186/s12883-016-0639-7. View

Teunissen C, Tumani H, Engelborghs S, Mollenhauer B . Biobanking of CSF: international standardization to optimize biomarker development. Clin Biochem. 2014; 47(4-5):288-92. DOI: 10.1016/j.clinbiochem.2013.12.024. View

Arrambide G, Tintore M, Montalban X . Oligoclonal bands do not represent dissemination in time in the 2017 revisions to the McDonald criteria. Mult Scler. 2019; 25(12):1690-1691. DOI: 10.1177/1352458519846103. View

10.

Link J, Ramanujam R, Auer M, Ryner M, Hassler S, Bachelet D . Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results. PLoS One. 2017; 12(2):e0170395. PMC: 5295710. DOI: 10.1371/journal.pone.0170395. View

11.

Poser C, Paty D, Scheinberg L, McDonald W, Davis F, Ebers G . New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983; 13(3):227-31. DOI: 10.1002/ana.410130302. View

12.

Edwards K, Garten L, Button J, OConnor J, Kamath V, Frazier C . Neurofilament light chain as an indicator of exacerbation prior to clinical symptoms in multiple sclerosis. Mult Scler Relat Disord. 2019; 31:59-61. DOI: 10.1016/j.msard.2019.03.016. View

13.

Weber M, Derfuss T, Metz I, Bruck W . Defining distinct features of anti-MOG antibody associated central nervous system demyelination. Ther Adv Neurol Disord. 2018; 11:1756286418762083. PMC: 5881972. DOI: 10.1177/1756286418762083. View

14.

. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95. DOI: 10.1067/mcp.2001.113989. View

15.

Kaunzner U, Al-Kawaz M, Gauthier S . Defining Disease Activity and Response to Therapy in MS. Curr Treat Options Neurol. 2017; 19(5):20. DOI: 10.1007/s11940-017-0454-5. View

16.

Jarius S, Eichhorn P, Franciotta D, Petereit H, Akman-Demir G, Wick M . The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature. J Neurol. 2016; 264(3):453-466. DOI: 10.1007/s00415-016-8360-4. View

17.

Petzold A . Applying the 2017 McDonald diagnostic criteria for multiple sclerosis. Lancet Neurol. 2018; 17(6):496-497. DOI: 10.1016/S1474-4422(18)30159-5. View

18.

Canto E, Reverter F, Morcillo-Suarez C, Matesanz F, Fernandez O, Izquierdo G . Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis. Mult Scler. 2011; 18(7):983-90. DOI: 10.1177/1352458511433063. View

19.

Kuhlmann T, Ludwin S, Prat A, Antel J, Bruck W, Lassmann H . An updated histological classification system for multiple sclerosis lesions. Acta Neuropathol. 2016; 133(1):13-24. DOI: 10.1007/s00401-016-1653-y. View

20.

Matute-Blanch C, Villar L, Alvarez-Cermeno J, Rejdak K, Evdoshenko E, Makshakov G . Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain. 2018; 141(4):1085-1093. DOI: 10.1093/brain/awy021. View